CN113614106A - 抗c5抗体用于治疗全身型重症肌无力的剂量和施用 - Google Patents

抗c5抗体用于治疗全身型重症肌无力的剂量和施用 Download PDF

Info

Publication number
CN113614106A
CN113614106A CN202080021230.XA CN202080021230A CN113614106A CN 113614106 A CN113614106 A CN 113614106A CN 202080021230 A CN202080021230 A CN 202080021230A CN 113614106 A CN113614106 A CN 113614106A
Authority
CN
China
Prior art keywords
antibody
patient
treatment
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080021230.XA
Other languages
English (en)
Chinese (zh)
Inventor
K·藤田
N·拉姆帕尔
W-J·潘
K·帕特拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Priority to CN202411307488.2A priority Critical patent/CN119326881A/zh
Publication of CN113614106A publication Critical patent/CN113614106A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080021230.XA 2019-02-14 2020-02-13 抗c5抗体用于治疗全身型重症肌无力的剂量和施用 Pending CN113614106A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411307488.2A CN119326881A (zh) 2019-02-14 2020-02-13 抗c5抗体用于治疗全身型重症肌无力的剂量和施用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962805350P 2019-02-14 2019-02-14
US62/805,350 2019-02-14
US201962814935P 2019-03-07 2019-03-07
US62/814,935 2019-03-07
PCT/US2020/018113 WO2020168079A1 (en) 2019-02-14 2020-02-13 Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411307488.2A Division CN119326881A (zh) 2019-02-14 2020-02-13 抗c5抗体用于治疗全身型重症肌无力的剂量和施用

Publications (1)

Publication Number Publication Date
CN113614106A true CN113614106A (zh) 2021-11-05

Family

ID=69954108

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080021230.XA Pending CN113614106A (zh) 2019-02-14 2020-02-13 抗c5抗体用于治疗全身型重症肌无力的剂量和施用
CN202411307488.2A Pending CN119326881A (zh) 2019-02-14 2020-02-13 抗c5抗体用于治疗全身型重症肌无力的剂量和施用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411307488.2A Pending CN119326881A (zh) 2019-02-14 2020-02-13 抗c5抗体用于治疗全身型重症肌无力的剂量和施用

Country Status (9)

Country Link
US (2) US20200331993A1 (https=)
EP (1) EP3924380A1 (https=)
JP (2) JP2022520107A (https=)
KR (2) KR20260046520A (https=)
CN (2) CN113614106A (https=)
AU (1) AU2020223298A1 (https=)
CA (1) CA3130300A1 (https=)
MX (1) MX2021009789A (https=)
WO (1) WO2020168079A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3024618A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
DE102021120603A1 (de) * 2020-08-24 2022-02-24 Nvidia Corporation Techniken des maschinellen lernens zur sauerstofftherapievorhersage unter verwendung von medizinischen bildgebungsdaten und klinischen metadaten
EP4281472A1 (en) * 2021-01-22 2023-11-29 Alexion Pharmaceuticals, Inc. Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody
US20250154232A1 (en) * 2021-07-14 2025-05-15 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
US20170342139A1 (en) * 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for Treatment of Refractory Generalized Myasthenia Gravis
WO2019023564A1 (en) * 2017-07-27 2019-01-31 Alexion Pharmaceutical, Inc. ANTI-C5 ANTIBODY FORMULATIONS WITH HIGH CONCENTRATION

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
CN118512588A (zh) * 2017-10-26 2024-08-20 亚力兄制药公司 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
US20170342139A1 (en) * 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for Treatment of Refractory Generalized Myasthenia Gravis
WO2019023564A1 (en) * 2017-07-27 2019-01-31 Alexion Pharmaceutical, Inc. ANTI-C5 ANTIBODY FORMULATIONS WITH HIGH CONCENTRATION

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALEXION PHARMACEUTICALS, INC.: "Study of ALXN1210 in complement inhibitor treatment-naive adult and adolescent participants with atypical hemolytic uremic syndrome (aHUS)", NCT02949128, 27 October 2016 (2016-10-27) *

Also Published As

Publication number Publication date
KR20210126045A (ko) 2021-10-19
KR20260046520A (ko) 2026-04-07
US20200331993A1 (en) 2020-10-22
JP2025092553A (ja) 2025-06-19
CA3130300A1 (en) 2020-08-20
JP2022520107A (ja) 2022-03-28
AU2020223298A1 (en) 2021-09-02
EP3924380A1 (en) 2021-12-22
WO2020168079A1 (en) 2020-08-20
MX2021009789A (es) 2021-11-17
CN119326881A (zh) 2025-01-21
US20250243264A1 (en) 2025-07-31

Similar Documents

Publication Publication Date Title
US20250243264A1 (en) Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis
KR20190012199A (ko) 난치성 전신 중증 근무력증의 치료를 위한 방법
JP2022512632A (ja) 発作性夜間ヘモグロビン尿症（ｐｎｈ）の処置のための抗ｃ５抗体の皮下投薬及び投与
CN116194478A (zh) 皮下（sc）施用抗c5抗体治疗补体相关病症
JP2025084932A (ja) 視神経脊髄炎スペクトラム障害の治療のための抗ｃ５抗体
US20260022164A1 (en) Compositions and methods for the treatment of neuromyelitis optica spectrum disorder
JP2022501378A (ja) 視神経脊髄炎の処置のためのエクリズマブ
US20250154232A1 (en) Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis
JP2021501213A (ja) ＩｇＥ介在アレルギー性疾患の治療
KR20250030978A (ko) 중증 근무력증의 치료를 위한 융합 폴리펩티드의 투여량 및 투여
KR20240004367A (ko) 중증근무력증 치료를 위한 항-cd19 항체의 사용
US20250066467A1 (en) Methods for the treatment of myasthenia gravis
EA046524B1 (ru) Доза и введение антител к c5 для лечения генерализованной миастении гравис
WO2021263056A1 (en) Dosage and administration of anti-c5 antibodies for treatment of amyotrophic lateral sclerosis
CN117440827A (zh) 使用抗cd19抗体治疗重症肌无力
EA050729B1 (ru) Антитело к с5 для лечения нейромиелита зрительного нерва со спектральным расстройством
CN117500827A (zh) 用于治疗皮肌炎（dm）的抗c5抗体的剂量和施用
EA052907B1 (ru) Применение антитела к cd19 для лечения миастении гравис

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211105